First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Reports of ChAdOx1 vaccine–associated thrombocytopenia and vascular adverse events have led to some countries restricting its use. Using a national prospective cohort, we estimated associations between exposure to first-dose ChAdOx1 or BNT162b2 vaccination and hematological and vascular adverse even...

Full description

Bibliographic Details
Main Authors:	Simpson, CR, Shi, T, Vasileiou, E, Katikireddi, SV, Kerr, S, Moore, E, McCowan, C, Agrawal, U, Shah, SA, Ritchie, LD, Murray, J, Pan, J, Bradley, DT, Stock, SJ, Wood, R, Chuter, A, Beggs, J, Stagg, HR, Joy, M, Tsang, RSM, de Lusignan, S, Hobbs, R, Lyons, RA, Torabi, F, Bedston, S, O'Leary, M, Akbari, A, McMenamin, J, Robertson, C, Sheikh, A
Format:	Journal article
Language:	English
Published:	Springer Nature 2021

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Similar Items